Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Thursday, May 22, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Price reaction · baseline $3.22 (2025-05-21 close) · hit after-hours · clean, no other SGMT news in the window
day 0 close
+5.9%
day 1 · peak
+7.1%
day 3
+5.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025.